Galapagos (GLPG) investor relations material

Executive summary

• Approved name change to Lakefront Biotherapeutics, effective May 8, 2026, reflecting a major transformation and strategic evolution, including new management and board appointments.

• Entered a binding agreement with Gilead to jointly acquire Ouro Medicines, adding the lead asset gamgertamig (a BCMA/CD3 T-cell engager for autoimmune diseases) and preclinical assets to the pipeline; collaboration expected to close in Q2 2026.

• Gamgertamig has shown rapid, durable responses and minimal cytokine release syndrome in over 60 patients across five autoimmune indications, and has received Fast Track and Orphan Drug Designation by FDA for AIHA and ITP.

• Wind-down of cell therapy activities is on track, with completion expected by end of Q3 2026.

• Board transition with Gino Santini appointed as new chair, bringing extensive pharma experience.

Financial highlights

• Q1 2026 net revenues were €6.5M, down 91% year-over-year, mainly due to prior year’s one-time or deferred income recognition.

• Operating loss improved to €63.7M from €158.7M last year, reflecting lower R&D and absence of restructuring charges.

• Net profit of €14.5M in Q1 2026, compared to a net loss of €153.4M in Q1 2025, driven by fair value adjustments and currency gains.

• Cash and financial investments totaled €2,982.2M at March 31, 2026.

• Net financial income rose to €77.7M, driven by fair value gains and currency exchange effects.

Outlook and guidance

• Year-end 2026 cash and investments expected at €1.975B–€2.05B, reflecting Ouro transaction and restructuring costs.

• Estimated 2026 cash spend related to Ouro: €775M–€790M, including upfront, transaction, and operating costs.

• One-time cash restructuring costs for cell therapy wind-down expected at €125M–€175M in 2026.

• Up to $500M available for business development outside Gilead partnership, including up to $150M for share repurchases.

• Majority of current cash (~€3B) to remain available for strategic transactions post-Ouro deal.